Evaluation of Cardiovascular Effects of Smoking Cessation in HIV Patients

Completed

Conditions studied: HIV Infections, Smokers

In brief

We will conduct a sub-study of "An Innovative Telephone Intervention for HIV+ Smokers," (NCT00502827) conducted by Drs. Gritz, Vidrine, and others. This is a randomized, prospective trial that will evaluate a cellular phone delivered counseling intervention versus standard of care for smoking cessation. In our sub-study, we will evaluate rates of progression in atherosclerosis in HIV/AIDS patients who quit smoking versus those who continue smoking by measuring carotid intima-media thickness(CIMT) and biomarkers of atherosclerosis at time point baseline, 1 year, and 3 year. The biomarkers measured include high-sensitivity Creactive protein, homocysteine, and IL-6. We will also evaluate rates of progression of CIMT in those who quit smoking versus those who continue smoking, based on race, sex, state of HIV disease, comorbid diseases, and lipid profile.

Key facts

Study ID

NCT00918073

Run by

The University of Texas Health Science Center, Houston

People needed

50

Starts

2007-11-01

Expected to finish

2013-04-01

Last updated by the study team

2013-05-07

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who meet eligibility criteria for "An innovative telephone intervention for HIV-positive smokers".
• Patients who consent to the sub-study.
• Patients who are able to participate in the study for 3 years.

You may not qualify if…

• Patients with a history of coronary bypass surgery, percutaneous coronary intervention, valve replacement, pacemaker or defibrillator implantation.

Where it is running

• Thomas Street Health Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.